This technology is a therapeutic approach that targets senescent cells to both reverse ultraviolet-induced skin photoaging and reduce melanoma progression.
Current approaches to treating photoaging rely on topical agents, cosmetic procedures, or sunscreens, which primarily address symptoms rather than the underlying cellular drivers of skin aging. Likewise, melanoma treatments often depend on surgery, chemotherapy, or immunotherapy, which can be costly, have significant side effects, and are not always effective in preventing disease progression. A growing body of evidence shows that the chronic accumulation of senescent cells contributes directly to both ultraviolet-induced skin aging and melanoma development, yet no therapies currently exist to selectively target these cells in patients. Addressing this gap could lead to more effective strategies for both reversing skin damage and improving cancer outcomes.
This technology leverages the selective elimination of senescent cells to address two major challenges in human health: ultraviolet-induced skin photoaging and melanoma progression. By inhibiting or removing senescent cells, the technology reduces the inflammatory signaling and tissue remodeling associated with skin thickening and collagen loss, while simultaneously limiting the ability of cancer cells to survive and proliferate.
The approach has been validated using both in vitro cellular systems and in vivo animal models, demonstrating improvements in skin structure as well as reduced tumor development.
IR CU25349
Licensing Contact: Jerry Kokoshka
